Natural Nrf2 activators in diabetes

Clinica Chimica Acta

Volumn 448, Issue , 2015, Pages 182-192

  Jiménez Osorio, Angélica Saraí ^a   González Reyes, Susana ^a   Pedraza Chaverri, José ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Curcumin; Diabetes; Gamma glutamate cysteine ligase; Glutathione peroxidase; Glutathione reductase; Heme oxygenase 1; Nrf2; Prediabetes; Resveratrol; Sulforaphane; Vitamin D

Indexed keywords

ACARBOSE; ACTINIDIA CALLOSA EXTRACT; ALLOXAN; ANKAFLAVIN; CHROMIUM; CURCUMIN; DIMERUMIC ACID; EUPHORBIA PEKINENSIS EXTRACT; GARLIC EXTRACT; GLUCOSE; GLYCYRRHIZA URALENSIS EXTRACT; GYNOSTEMMA PENTAPHYLLUM EXTRACT; INSULIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MAGNOLIA OFFICINALIS EXTRACT; METFORMIN; METHYLGLYOXAL; NATURAL PRODUCT; PLANT EXTRACT; PROTEIN KINASE C; PRUNELLA VULGARIS EXTRACT; PUERARIA LOBATA EXTRACT; REACTIVE OXYGEN METABOLITE; RESVERATROL; STREPTOZOCIN; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZINC; ANTIOXIDANT; BIOLOGICAL PRODUCT; NFE2L2 PROTEIN, HUMAN;

ACTINIDIA; ACTINIDIA CALLOSA; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMUTAGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; COMORBIDITY; CYTOPLASM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE COURSE; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; EUPHORBIA; EUPHORBIA PEKINENSIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; GLYCEMIC INDEX; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; KIDNEY DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MONASCUS; MORBIDITY; MORTALITY; NEUROPATHY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PUERARIA LOBATA; QUALITY OF LIFE; RETINOPATHY; REVIEW; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRADITIONAL MEDICINE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; AGONISTS; METABOLISM;

FUNGI;

ANTIOXIDANTS; BIOLOGICAL PRODUCTS; DIABETES MELLITUS; HUMANS; NF-E2-RELATED FACTOR 2;

EID: 84937232376     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.07.009     Document Type: Review

References (148)

1. International Diabetes Federation Diabetes Atlas 2013, (http://www.idf.org/diabetesatlas). 6th edn.
2. Boyle J.P., Thompson T.J., Gregg E.W., Barker L.E., Williamson D.F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metrics 2010, 8:29.
3. Liang K., Sun Y., Li W.J., Zhang X.P., Li C.Q., Yang W.F., et al. Diagnostic efficiency of hemoglobin A1c for newly diagnosed diabetes and prediabetes in community-based Chinese adults aged 40years or older. Diabetes Technol. Ther. 2014, 16:853-857.
4. Mukai N., Doi Y., Ninomiya T., Hirakawa Y., Nagata M., Yoshida D., et al. Trends in the prevalence of type 2 diabetes and prediabetes in community-dwelling Japanese subjects: the Hisayama study. J. Diabetes Investig. 2014, 5:162-169.
5. Wise J. A third of adults in England have "prediabetes", study says. BMJ 2014, 348:g3791.
6. Gujral U.P., Narayan K.M., Pradeepa R.G., Deepa M., Ali M.K., Anjana R.M., et al. Comparing type 2 diabetes, prediabetes, and their associated risk factors in Asian Indians in India and in the U.S.: the CARRS and MASALA studies. Diabetes Care 2015, 38:1312-1318.
7. Mota M., Popa S.G., Mota E., Mitrea A., Catrinoiu D., Cheta D.M., et al. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. J. Diabetes 2015, 10.1111/1753-0407.12297.
8. World Health Organization, International Diabetes Federation Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation 2006, World Health Organization, Geneva.
9. American Diabetes Association Standards of medical care in diabetes-2014. Diabetes Care 2014, 37:14-80.
10. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008, 359:1577-1589.
11. Diabetes Prevention Program Research Group 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes study. Lancet 2009, 374:1677-1686.
12. Alibasic E., Ramic E., Alic A. Prevention of diabetes in family medicine. Mater. Sociomed. 2013, 25:80-82.
13. Narayan K.M.V., Imperatore G., Benjamin S.M., Engelgau M.M. Targeting people with pre-diabetes: lifestyle interventions should also be aimed at people with pre-diabetes. BMJ 2002, 325:403-404.
14. Maruthur N.M., Ma Y., Delahanty L.M., Nelson J.A., Aroda V., White N.H., et al. Diabetes Prevention Program Research Group: early response to preventive strategies in the Diabetes Prevention Program. J. Gen. Intern. Med. 2013, 28:1629-1636.
15. Chiu J., Khan Z.A., Farhangkhoee H., Chakrabarti S. Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition 2009, 25:964-972.
16. Bahadoran Z., Mirmiran P., Azizi F. Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. J. Diabetes Metab. Disord. 2013, 12:43.
17. Bahadoran Z., Mirmiran P., Azizi F. Potential efficacy of broccoli sprouts as a unique supplement for management of type 2 diabetes and its complications. J. Med. Food 2013, 16:375-382.
18. Surh Y.J., Kundu J.K., Na H.K. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008, 74:1526-1539.
19. Yoh K., Hirayama A., Ishizaki K., Yamada A., Takeuchi M., Yamagishi S., et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008, 13:1159-1170.
20. Lowe L.P., Liu K., Greenland P., Metzger B.E., Dyer A.R., Stamler J. Diabetes, asymptomatic hyperglycaemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry study. Diabetes Care 1997, 20:163-169.
21. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346:393-403.
22. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329:977-986.
23. Ackermann R.T., Finch E.A., Brizendine E., Zhou H., Marrero D.G. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot study. Am. J. Prev. Med. 2008, 35:357-363.
24. Kramer C.K., Choi H., Zinman B., Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function. Diabetes Care 2014, 37:1116-1123.
25. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
26. Ceriello A., Esposito K., Piconi L., Ihnat M.A., Thorpe J.E., Testa R., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57:1349-1354.
27. Farmer A., Wade A., Goyder E., Yudkin P., French D., Craven A., et al. Impact of self-monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007, 335:132.
28. Polonsky W.H., Fisher L., Schikman C.H., Hinnen D.A., Parkin C.G., Jelsovsky Z., et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011, 34:262-267.
29. Ang S.H., Thevarajah M., Alias Y., Khor S.M. Current aspects in hemoglobin A1c detection: a review. Clin. Chim. Acta 2015, 439:202-211.
30. Wolf A.M., Conaway M.R., Crowther J.Q., Hazen K.Y., Nadler J.L., Oneida B., et al. Improving Control with Activity and Nutrition (ICAN) study: translating lifestyle intervention to practice in obese patients with type 2 diabetes. Diabetes Care 2004, 27:1570-1576.
31. Lindström J., Ilanne-Parikka P., Peltonen M., Aunola S., Eriksson J.G., Hemiö K., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention study. Lancet 2006, 368:1673-1679.
32. Hostalek U., Gwilt M., Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 2015, 10.1007/s40265-015-0416-8.
33. Orchard T.J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 2005, 142:611-619.
34. Diabetes Prevention Program Research Group The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012, 35:723-730.
35. Gauthier B., Singh S.R., Virani A., Staples H., Colbourne A. Perspectives and experiences of health care professionals and patients regarding treatments for type 2 diabetes. Can. Pharm. J. (Ott) 2014, 147:45-54.
36. Lipska K.J., Bailey C.J., Inzucchi S.E. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2014, 34:1431-1437.
37. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. STOP-NIDDM Trial Research Group: acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.
38. Zeymer U., Schwarzmaier-D'assie A., Petzinna D., Chiasson J.L. STOP-NIDDM Trial Research Group: effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. Eur. J. Cardiovasc. Prev. Rehabil. 2004, 11:412-415.
39. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
40. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
41. Blonde L., Merilainen M., Karwe V., Raskin P., TITRATE Study Group Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets. The TITRATE study. Diabetes Obes. Metab. 2009, 11:623-631.
42. Bohan E.M. Hypoglycemia due to insulin. A major medical problem. Del. Med. J. 1961, 33:297-299.
43. Wallia A., Molitch M.E. Insulin therapy for type 2 diabetes mellitus. JAMA 2014, 311:2315-2325.
44. Clark A.L., Best C.J., Fisher S.J. Even silent hypoglycemia induces cardiac arrhythmias. Diabetes 2014, 63:1457-1459.
45. Evert A.B., Boucher J.L., Cypress M., Dunbar S.A., Franz M.J., Mayer-Davis E.J., et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2014, 37:120-143.
46. Ley S.H., Hamdy O., Mohan V., Hu F.B. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet 2014, 383:1999-2007.
47. Motohashi H., O'Connor T., Katsuoka F., Engel J.D., Yamamoto M. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 2002, 294:1-12.
48. Hayes J.D., Dinkova-Kostova A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 2014, 39:199-218.
49. Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 2004, 24:7130-7139.
50. Zhang D.D., Lo S.C., Cross J.V., Templeton D.J., Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 2004, 24:10941-10953.
51. Katoh Y., Iida K., Kang M.I., Kobayashi A., Mizukami M., Tong K.I., et al. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch. Biochem. Biophys. 2005, 433:342-350.
52. Kawai Y., Garduño L., Theodore M., Yang J., Arinze I.J. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J. Biol. Chem. 2011, 286:7629-7640.
53. Baird L., Dinkova-Kostova A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 2011, 85:241-272.
54. Turpaev K.T. Keap1-Nrf2 signaling pathway: mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles. Biochemistry 2013, 78:147-166.
55. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 1997, 236:313-322.
56. Li H., Wang F., Zhang L., Cao Y., Liu W., Hao J., et al. Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell. Signal. 2011, 23:1625-1632.
57. Tan Y., Ichikawa T., Li J., Si Q., Yang H., Chen X., et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 2011, 60:625-633.
58. Ungvari Z., Bailey-Downs L., Gautam T., Jimenez R., Losonczy G., Zhang C., et al. Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:1133-1140.
59. Wang X., Wang Z., Liu J.Z., Hu J.X., Chen H.L., Li W.L., et al. Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte. Toxicol. In Vitro 2011, 25:839-847.
60. Mozzini C., Garbin U., Stranieri C., Pasini A., Solani E., Tinelli I.A., et al. Endoplasmic reticulum stress and Nrf2 repression in circulating cells of type 2 diabetic patients without the recommended glycemic goals. Free Radic. Res. 2015, 49:244-252.
61. Bitar M.S., Al-Mulla F. A defect in Nrf2 signaling constitutes a mechanism for cellular stress hypersensitivity in a genetic rat model of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2011, 301:1119-1129.
62. Liu T.S., Pei Y.H., Peng Y.P., Chen J., Jiang S.S., Gong J.B. Oscillating high glucose enhances oxidative stress and apoptosis in human coronary artery endothelial cells. J. Endocrinol. Investig. 2014, 37:645-651.
63. He X., Kan H., Cai L., Ma Q. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J. Mol. Cell. Cardiol. 2009, 46:47-58.
64. Jiang T., Huang Z., Lin Y., Zhang Z., Fang D., Zhang D.D. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59:850-860.
65. Uruno A., Furusawa Y., Yagishita Y., Fukutomi T., Muramatsu H., Negishi T., et al. The Keap1-Nrf2 system prevents onset of diabetes mellitus. Mol. Cell. Biol. 2013, 33:2996-3010.
66. Jiménez-Osorio A.S., Picazo A., González-Reyes S., Barrera-Oviedo D., Rodríguez-Arellano M.E., Pedraza-Chaverri J. Nrf2 and redox status in prediabetic and diabetic patients. Int. J. Mol. Sci. 2014, 15:20290-20305.
67. Lee Y.J., Kwon S.B., An J.M., Kim C.H., Lee S.H., Choi C.Y., et al. Increased protein oxidation and decreased expression of nuclear factor E2-related factor 2 protein in skin tissue of patients with diabetes. Clin. Exp. Dermatol. 2015, 40:192-200.
68. Pi J., Zhang Q., Fu J., Woods C.G., Hou Y., Corkey B.E., et al. ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol. Appl. Pharmacol. 2010, 244:77-83.
69. Pugazhenthi S., Akhov L., Selvaraj G., Wang M., Alam J. Regulation of heme oxygenase-1 expression by demethoxy curcuminoids through Nrf2 by a PI3-kinase/Akt-mediated pathway in mouse beta-cells. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E645-E655.
70. Song M.Y., Kim E.K., Moon W.S., Park J.W., Kim H.J., So H.S., et al. Sulforaphane protects against cytokine- and streptozotocin-induced beta-cell damage by suppressing the NF-kappaB pathway. Toxicol. Appl. Pharmacol. 2009, 235:57-67.
71. Kang K.A., Kim J.S., Zhang R., Piao M.J., Maeng Y.H., Kang M.Y., et al. KIOM-4 protects against oxidative stress-induced mitochondrial damage in pancreatic β-cells via Its antioxidant effects. Evid. Based Complement. Alternat. Med. 2011, 2011:978682.
72. Xue M., Qian Q., Adaikalakoteswari A., Rabbani N., Babaei-Jadidi R., Thornalley P.J. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008, 57:2809-2817.
73. Kim S.H., Kim S.H., Choi M., Lee Y., Kim Y.O., Ahn D.S., et al. Natural therapeutic magnesium lithospermate B potently protects the endothelium from hyperglycaemia-induced dysfunction. Cardiovasc. Res. 2010, 87:713-722.
74. Hwang S.M., Lee Y.J., Yoon J.J., Lee S.M., Kim J.S., Kang D.G., Lee H.S. Prunella vulgaris suppresses HG-induced vascular inflammation via Nrf2/HO-1/eNOS activation. Int. J. Mol. Sci. 2012, 13:1258-1268.
75. Velmurugan G.V., Sundaresan N.R., Gupta M.P., White C. Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc. Res. 2013, 100:143-150.
76. Tsai C.Y., Wang C.C., Lai T.Y., Tsu H.N., Wang C.H., Liang H.Y., et al. Antioxidant effects of diallyl trisulfide on high glucose-induced apoptosis are mediated by the PI3K/Akt-dependent activation of Nrf2 in cardiomyocytes. Int. J. Cardiol. 2013, 168:1286-1297.
77. Cheng A.S., Cheng Y.H., Chiou C.H., Chang T.L. Resveratrol upregulates Nrf2 expression to attenuate methylglyoxal-induced insulin resistance in Hep G2 cells. J. Agric. Food Chem. 2012, 60:9180-9187.
78. Lee B.H., Hsu W.H., Hsu Y.W., Pan T.M. Dimerumic acid attenuates receptor for advanced glycation endproducts signal to inhibit inflammation and diabetes mediated by Nrf2 activation and promotes methylglyoxal metabolism into d-lactic acid. Free Radic. Biol. Med. 2013, 60:7-16.
79. Zhang X., Zhao Y., Chu Q., Wang Z.Y., Li H., Chi Z.H. Zinc modulates high glucose-induced apoptosis by suppressing oxidative stress in renal tubular epithelial cells. Biol. Trace Elem. Res. 2014, 158:259-267.
80. Hsu Y.Y., Tseng Y.T., Lo Y.C. Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth. Toxicol. Appl. Pharmacol. 2013, 272:787-796.
81. Lee C.C., Lee B.H., Wu S.C. Actinidia callosa peel (kiwi fruit) ethanol extracts protected neural cells apoptosis induced by methylglyoxal through Nrf2 activation. Pharm. Biol. 2014, 52:628-636.
82. Ramprasath T., Kumar P.H., Puhari S.S., Murugan P.S., Vasudevan V., Selvam G.S. l-Arginine ameliorates cardiac left ventricular oxidative stress by upregulating eNOS and Nrf2 target genes in alloxan-induced hyperglycemic rats. Biochem. Biophys. Res. Commun. 2012, 428:389-394.
83. Zhang Z., Wang S., Zhou S., Yan X., Wang Y., Chen J., et al. Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. J. Mol. Cell. Cardiol. 2014, 77:42-52.
84. Lee B.H., Hsu W.H., Chang Y.Y., Kuo H.F., Hsu Y.W., Pan T.M. Ankaflavin: a natural novel PPARγ agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo. Free Radic. Biol. Med. 2012, 53:2008-2016.
85. Wang X., Liu R., Zhang W., Zhang X., Liao N., Wang Z., et al. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-sinflammatory effects. Mol. Cell. Endocrinol. 2013, 376:70-80.
86. Gao D., Zhao M., Qi X., Liu Y., Li N., Liu Z., Bian Y. Hypoglycemic effect of Gynostemma pentaphyllum saponins by enhancing the Nrf2 signaling pathway in STZ-inducing diabetic rats. Arch. Pharm. Res. 2014, 10.1007/s12272-014-0441-2.
87. Yang Y., Li W., Li Y., Wang Q., Gao L., Zhao J. Dietary Lycium barbarum polysaccharide induces Nrf2/ARE pathway and ameliorates insulin resistance induced by high-fat via activation of PI3K/AKT signaling. Oxidative Med. Cell. Longev. 2014, 2014:145641.
88. Chang W.C., Wu S.C., Xu K.D., Liao B.C., Wu J.F., Cheng A.S. Scopoletin protects against methylglyoxal-induced hyperglycemia and insulin resistance mediated by suppression of advanced glycation endproducts (AGEs) generation and anti-glycation. Molecules 2015, 20:2786-2801.
89. Palsamy P., Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim. Biophys. Acta 1812, 2011:719-731.
90. Zheng H., Whitman S.A., Wu W., Wondrak G.T., Wong P.K., Fang D., et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011, 60:3055-3066.
91. Arambašić J., Mihailović M., Uskoković A., Dinić S., Grdović N., Marković J., et al. Alpha-lipoic acid upregulates antioxidant enzyme gene expression and enzymatic activity in diabetic rat kidneys through an O-GlcNAc-dependent mechanism. Eur. J. Nutr. 2013, 52:1461-1473.
92. Nakai K., Fujii H., Kono K., Goto S., Kitazawa R., Kitazawa S., et al. Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. Am. J. Hypertens. 2014, 27:586-595.
93. Sahin K., Tuzcu M., Orhan C., Gencoglu H., Ulas M., Atalay M., et al. The effects of chromium picolinate and chromium histidinate administration on NF-κB and Nrf2/HO-1 pathway in the brain of diabetic rats. Biol. Trace Elem. Res. 2012, 150:291-296.
94. Wang Y., Zhang Z., Guo W., Sun W., Miao X., Wu H., et al. Sulforaphane reduction of testicular apoptotic cell death in diabetic mice is associated with the up regulation of Nrf2 expression and function. Am. J. Physiol. Endocrinol. Metab. 2014, 307:E14-E23.
95. Kang K.A., Kim J.S., Zhang R., Piao M.J., Chang W.Y., Kim K.C. Protective mechanism of KIOM-4 against streptozotocin induced diabetic cells: involvement of heme oxygenase-1. Biotechnol. Bioprocess Eng. 2009, 14:295-301.
96. Fiorentino A., D'Abrosca B., Pacifico S., Mastellone C., Scognamiglio M., Monaco P. Identification and assessment of antioxidant capacity of phytochemicals from kiwi fruits. J. Agric. Food Chem. 2009, 57:4148-4155.
97. Wang L., Gao S., Jiang W., Luo C., Xu M., Bohlin L., et al. Antioxidative dietary compounds modulate gene expression associated with apoptosis, DNA repair, inhibition of cell proliferation and migration. Int. J. Mol. Sci. 2014, 15:16226-16245.
98. Masjedi F., Gol A., Dabiri S. Preventive effect of garlic (Allium sativum L.) on serum biochemical factors and histopathology of pancreas and liver in streptozotocin-induced diabetic rats. Iran. J. Pharm. Res. 2013, 12:325-338.
99. Mathew P.T., Augusti K.T. Studies on the effect of allicin (diallyldisulphide-oxide) on alloxan diabetes I. Hypoglycemic action and enhancement of serum insulin effect and glycogen synthesis. Indian J. Biochem. Biophys. 1973, 10:209-212.
100. Padiya R., Khatua T.N., Bagul P.K., Kuncha M., Banerjee S.K. Garlic improves insulin sensitivity and associated metabolic syndromes in fructose fed rats. Nutr. Metab. 2011, 8:53.
101. Padiya R., Chowdhury D., Borkar R., Srinivas R., Pal Bhadra M., Banerjee S.K. Garlic attenuates cardiac oxidative stress via activation of PI3K/AKT/Nrf2-Keap1 pathway in fructose-fed diabetic rat. PLoS One 2014, 9:e94228.
102. Trujillo J., Granados-Castro L.F., Zazueta C., Andérica-Romero A.C., Chirino Y.I., Pedraza-Chaverrí J. Mitochondria as a target in the therapeutic properties of curcumin. Arch. Pharm. (Weinheim, Ger.) 2014, 347:873-884.
103. Weisberg S.P., Leibel R., Tortoriello D.V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149:3549-3558.
104. Rivera-Mancía S., Lozada-García M.C., Pedraza-Chaverri J. Experimental evidence for curcumin and its analogs for management of diabetes mellitus and its associated complications. Eur. J. Pharmacol. 2015, 756:30-37.
105. Esatbeyoglu T., Huebbe P., Ernst I.M., Chin D., Wagner A.E., Rimbach G. Curcumin-from molecule to biological function. Angew. Chem. Int. Ed. Engl. 2012, 51:5308-5332.
106. He H.J., Wang G.Y., Gao Y., Ling W.H., Yu Z.W., Jin T.R. Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. World J. Diabetes 2012, 3:94-104.
107. Zhang D.W., Fu M., Gao S.H., Liu J.L. Curcumin and diabetes: a systematic review. Evid. Based Complement. Alternat. Med. 2013, 2013:636053.
108. Zhang X., Liang D., Guo L., Liang W., Jiang Y., Li H., Zhao Y., Lu S., Chi Z.H. Curcumin protects renal tubular epithelial cells from high glucose-induced epithelial-to-mesenchymal transition through Nrf2-mediated upregulation of heme oxygenase-1. Mol. Med. Rep. 2015, 12:1347-1355.
109. Suresh Babu P., Srinivasan K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol. Cell. Biochem. 1998, 181:87-96.
110. Zuo Z.F., Zhang Q., Liu X.Z. Protective effects of curcumin on retinal Müller cell in early diabetic rats. Int. J. Ophthalmol. 2013, 6:422-424.
111. Kowluru R.A., Koppolu P., Chakrabarti S., Chen S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic. Res. 2003, 37:1169-1180.
112. Negrette-Guzmán M., Huerta-Yepez S., Tapia E., Pedraza-Chaverri J. Modulation of mitochondrial functions by the indirect antioxidant sulforaphane: a seemingly contradictory dual role and an integrative hypothesis. Free Radic. Biol. Med. 2013, 65:1078-1089.
113. Choi K.M., Lee Y.S., Kim W., Kim S.J., Shin K.O., Yu J.Y., et al. Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice. J. Nutr. Biochem. 2014, 25:201-207.
114. Shang G., Tang X., Gao P., Guo F., Liu H., Zhao Z., et al. Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3 beta/Fyn/Nrf2 signaling pathway. J. Nutr. Biochem. 2015, 26:596-606.
115. Shakibaei M., Harikumar K.B., Aggarwal B.B. Resveratrol addiction: to die or not to die. Mol. Nutr. Food Res. 2009, 53:115-128.
116. Méndez-Del Villar M., González-Ortiz M., Martínez-Abundis E., Pérez-Rubio K.G., Lizárraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 2014, 12:497-501.
117. Szkudelski T., Szkudelska K. Anti-diabetic effects of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215:34-39.
118. Sadi G., Bozan D., Yildiz H.B. Redox regulation of antioxidant enzymes: post-translational modulation of catalase and glutathione peroxidase activity by resveratrol in diabetic rat liver. Mol. Cell. Biochem. 2014, 393:111-122.
119. Kumar A., Negi G., Sharma S.S. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms. Curr. Med. Chem. 2013, 20:4640-4645.
120. Patakova P. Monascus secondary metabolites: production and biological activity. J. Ind. Microbiol. Biotechnol. 2013, 40:169-181.
121. Hsu W.H., Lee B.H., Lu I.J., Pan T.M. Ankaflavin and monascin regulate endothelial adhesion molecules and endothelial NO synthase (eNOS) expression induced by tumor necrosis factor-a (TNF-a) in human umbilical vein endothelial cells (HUVECs). J. Agric. Food Chem. 2012, 60:1666-1672.
122. Lee C.L., Kung Y.H., Wu C.L., Hsu Y.W., Pan T.M. Monascin and ankaflavin act as novel hypolipidemic and high-density lipoprotein cholesterol-raising agents in red mold dioscorea. J. Agric. Food Chem. 2010, 58:9013-9019.
123. Mohammadi A., Sahebkar A., Iranshahi M., Amini M., Khojasteh R., Ghayour-Mobarhan M., et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother. Res. 2012, 27:374-379.
124. Ganjali S., Sahebkar A., Mahdipour E., Jamialahmadi K., Torabi S., Akhlaghi S., et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. Sci. World J. 2014, 2014:898361.
125. Panahi Y., Khalili N., Hosseini M.S., Abbasinazari M., Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther. Med. 2014, 22:851-857.
126. Chuengsamarn S., Rattanamongkolgul S., Luechapudiporn R., Phisalaphong C., Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012, 35:2121-2127.
127. Na L.X., Li Y., Pan H.Z., Zhou X.L., Sun D.J., Meng M., et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol. Nutr. Food Res. 2013, 57:1569-1577.
128. Chuengsamarn S., Rattanamongkolgul S., Phonrat B., Tungtrongchitr R., Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J. Nutr. Biochem. 2014, 25:144-150.
129. Khajehdehi P., Pakfetrat M., Javidnia K., Azad F., Malekmakan L., Nasab M.H., et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand. J. Urol. Nephrol. 2011, 45:365-370.
130. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32:537-541.
131. Knop F.K., Konings E., Timmers S., Schrauwen P., Holst J.J., Blaak E.E. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet. Med. 2013, 30:1214-1218.
132. Poulsen M.M., Vestergaard P.F., Clasen B.F., Radko Y., Christensen L.P., Stødkilde-Jørgensen H., et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62:1186-1195.
133. Sobenin I.A., Nedosugova L.V., Filatova L.V., Balabolkin M.I., Gorchakova T.V., Orekhov A.N. Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study. Acta Diabetol. 2008, 45:1-6.
134. Bahadoran Z., Tohidi M., Nazeri P., Mehran M., Azizi F., Mirmiran P. Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial. Int. J. Food Sci. Nutr. 2012, 63:767-771.
135. Sugden J.A., Davies J.I., Witham M.D., Morris A.D., Struthers A.D. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 2008, 25:320-325.
136. de Boer I.H., Tinker L.F., Connelly S., Curb J.D., Howard B.V., Kestenbaum B., et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008, 31:701-707.
137. Avenell A., Cook J.A., MacLennan G.S., McPherson G.C. RECORD trial group. Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 2009, 38:606-609.
138. von Hurst P.R., Stonehouse W., Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br. J. Nutr. 2010, 103:549-555.
139. Mitri J., Dawson-Hughes B., Hu F.B., Pittas A.G. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the calcium and vitamin D for diabetes mellitus (CaDDM) randomized controlled trial. Am. J. Clin. Nutr. 2011, 94:486-494.
140. Soric M.M., Renner E.T., Smith S.R. Effect of daily vitamin D supplementation on HbA1c in patients with uncontrolled type 2 diabetes mellitus: a pilot study. J Diabetes 2012, 4:104-105.
141. Alkharfy K.M., Al-Daghri N.M., Sabico S.B., Al-Othman A., Moharram O., Alokail M.S., et al. Vitamin D supplementation in patients with diabetes mellitus type 2 on different therapeutic regimens: a one-year prospective study. Cardiovasc. Diabetol. 2013, 12:113.
142. Breslavsky A., Frand J., Matas Z., Boaz M., Barnea Z., Shargorodsky M. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients. Clin. Nutr. 2013, 32:970-975.
143. Davidson M.B., Duran P., Lee M.L., Friedman T.C. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 2013, 36:260-266.
144. Salehpour A., Shidfar F., Hosseinpanah F., Vafa M., Razaghi M., Amiri F. Does vitamin D3 supplementation improve glucose homeostasis in overweight or obese women? A double-blind, randomized, placebo-controlled clinical trial. Diabet. Med. 2013, 30:1477-1481.
145. Yiu Y.F., Yiu K.H., Siu C.W., Chan Y.H., Li S.W., Wong L.Y., et al. Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. Atherosclerosis 2013, 227:140-146.
146. Ryu O.H., Chung W., Lee S., Hong K.S., Choi M.G., Yoo H.J. The effect of high-dose vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 diabetes. Korean J. Intern. Med. 2014, 29:620-629.
147. Sorkin J.D., Vasaitis T.S., Streeten E., Ryan A.S., Goldberg A.P. Evidence for threshold effects of 25-hydroxyvitamin D on glucose tolerance and insulin resistance in black and white obese postmenopausal women. J. Nutr. 2014, 144:734-742.
148. Di Cesar D.J., Ploutz-Snyder R., Weinstock R.S., Moses A.M. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care 2006, 29:174.